Tsiailanis, A.D.; Tellis, C.C.; Papakyriakopoulou, P.; Kostagianni, A.D.; Gkalpinos, V.; Chatzigiannis, C.M.; Kostomitsopoulos, N.; Valsami, G.; Tselepis, A.D.; Tzakos, A.G.
Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen. Molecules 2023, 28, 2311.
https://doi.org/10.3390/molecules28052311
AMA Style
Tsiailanis AD, Tellis CC, Papakyriakopoulou P, Kostagianni AD, Gkalpinos V, Chatzigiannis CM, Kostomitsopoulos N, Valsami G, Tselepis AD, Tzakos AG.
Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen. Molecules. 2023; 28(5):2311.
https://doi.org/10.3390/molecules28052311
Chicago/Turabian Style
Tsiailanis, Antonios D., Constantinos C. Tellis, Paraskevi Papakyriakopoulou, Androniki D. Kostagianni, Vasileios Gkalpinos, Christos M. Chatzigiannis, Nikolaos Kostomitsopoulos, Georgia Valsami, Alexandros D. Tselepis, and Andreas G. Tzakos.
2023. "Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen" Molecules 28, no. 5: 2311.
https://doi.org/10.3390/molecules28052311
APA Style
Tsiailanis, A. D., Tellis, C. C., Papakyriakopoulou, P., Kostagianni, A. D., Gkalpinos, V., Chatzigiannis, C. M., Kostomitsopoulos, N., Valsami, G., Tselepis, A. D., & Tzakos, A. G.
(2023). Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen. Molecules, 28(5), 2311.
https://doi.org/10.3390/molecules28052311
